Upneeq (soln)
| Upneeq (soln) | |
|---|---|
| DOSAGE | 1gtt into one or both ptotic eye(s) once daily |
| GENERIC | oxymetazoline hydrochloride ophthalmic solution 0.1% |
| SIZE | 0.3 mL (30 pack or 90 pack) |
| INDICATIONS | Treatment of acquired blepharoptosis in adults |
| MECHANISM OF ACTION | Alpha-adrenergic agonists |
| MICROBIOLOGY | Oxymetazoline is an alpha adrenoceptor agonist targeting a subset of adrenoreceptors in Mueller’s muscle of the eyelid |
| CONTRAINDICATIONS & WARNINGS | Hypersensitivity to any component of the product |
| PEDIATRIC USE | Safety and effectiveness of UPNEEQ have not been established in pediatric patients under 13 years of age |
| PREGNANCY | There are no available data on UPNEEQ use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Oxymetazoline is category C |
| NOTE | Remove contact lenses prior to use; reinsert 15 minutes following administration |
| Prior assessment of possible underlying disease such as Horner's, myasthenia gravis, etc. is required. Alpha agonist implications for various cardiovascular conditions and Sjögren’s syndrome must be considered. May increase the risk of narrow-angle glaucoma. | |
